Literature DB >> 9812662

[Clinical study on relationship between liver-blood stasis and liver fibrosis].

Z M Tang1, Q J Ru, Z E Zhang.   

Abstract

OBJECTIVE: Exploring the relationship between Liver-Blood Stasis (LBS) and liver fibrosis (LF) to lay a theoretical foundation of rational using traditional Chinese medicines against LF.
METHODS: Human procollagen peptide III (hPC III), hyaluronic acid (HA), laminin (LN) in the sera of 35 patients with hepatopathy and Blood Stasis Syndrome (HP-BS) and 35 patients with hepatopathy and Non-Blood Stasis Syndrome (HP-NBS) were measured by radioimmunoassay. Thirty healthy subjects were taken as control. Correlation analysis between the degrees of LBS and those of the serum indexes of LF was made.
RESULTS: (1) hPC III, HA, LN in the sera of the patients with HP-BS were markedly higher than those in the sera of the patients with HP-NBS, but the latter were markedly higher than healthy subjects. (2) Degrees of LBS correlated closely with those of LF. (3) (Xuefu Zhuyu Decoction XFZYD) not only might improve the degrees of LBS but also decline the serum LF indexes. Nevertheless, the curative effects in early period of taking the herbs only showed serum HA dropped.
CONCLUSION: The nature of LF in traditional Chinese medicine concept is mainly LBS. The degrees of LBS might reflect those of LF to a certain extent. XFZYD showed effective in declining serum LF indexes but it needs at least 2 months.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9812662

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis.

Authors:  Min Zheng; Wei-Min Cai; Hong-Lei Weng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  The Score Model Containing Chinese Medicine Syndrome Element of Blood Stasis Presented a Better Performance Compared to APRI and FIB-4 in Diagnosing Advanced Fibrosis in Patients with Chronic Hepatitis B.

Authors:  Xiao-Ling Chi; Mei-Jie Shi; Huan-Ming Xiao; Yu-Bao Xie; Gao-Shu Cai
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-20       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.